top of page
Search

FY22 CDMRP funding opportunities! Know before you apply...


CDMRP funding opportunities for fiscal year 2022 are available! Several programs have released their FY22 Program Announcements (PAs), including those for research in ALS; autism; breast, lung, prostate and ovarian cancers; epilepsy; orthotics and prosthetics; spinal cord injury; and tuberous sclerosis. The larger Peer Reviewed Cancer Research Program (PRCRP) and Peer Reviewed Medical Research Program (PRMRP) PAs have also been released.


PRCRP covers many cancers not covered by other stand-alone programs, but it should be noted that a) there are listed focus areas on the individual announcements and b) cancers covered by other CDMRP programs cannot be funded by PRCRP. The award types this year are many and varied. There are Career Development Awards for junior investigators, Translational Team Science Awards (multi-PI), a Convergent Science Cancer Consortium Development Award (with a multidisciplinary focus), a Behavioral Health Science Award, and Idea and Impact Awards geared toward early-stage research.


For FY22, PRMRP is seeking applications for a long list of focus areas under 9 umbrella categories: Autoimmune Disorders and Immunology, Cardiovascular Health, Hemorrhage Control and Blood Products, Infectious Diseases, Internal Medicine, Neuroscience, Nutrition and Metabolism, Orthopedic Medicine, and Respiratory Health. Each category has a unique set of strategic goals. For all focus areas, PRMRP is offering funding for 5 award types: Clinical Trial Award, Discovery Award, Focused Program Award, Investigator-Initiated Research Award, and Technology/Therapeutic Development Award. These opportunities run the gamut from early-stage (Discovery) to clinical trial and everything in between, to the unique Focused Program Award, which aims to bring together multiple investigators looking at a defined problem in different but synergistic ways.


Some of these opportunities may be similar to those offered by the NIH or other funding agencies (e.g., the Investigator-Initiated Research Award is somewhat like an R01), they all have in common carefully curated lists of foci and/or strategic priorities and the polestar of funding high-impact research. When seeking CDMRP funding, reading the PA carefully is critical to funding success. All applications should be uniquely tailored to the PA. In my experience as a Scientific Review Officer, applications that were obviously recycled from applying to other agencies stood out like sore thumbs and scored poorly in peer review, even if the research proposed was well supported and crafted. CDMRP wants to fund work that fits their mission.


Of course, it takes extra effort to tailor an application to the unique requirements of a CDMRP PA, and this might be time you can’t find in an already packed schedule. Hiring Artemis Editing can both save you that time and give you access to an experienced insider’s view on the CDMRP application review process. I will take a thorough and careful look at the PA and your application and offer suggestions and/or edits to not only ensure compliance but also craft an application that stands out to peers for quality AND clear alignment with program objectives.


Contact me for more details!

23 views0 comments

Comments


bottom of page